Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lycium barbarum glycopeptide
- Development stage
- Preclinical
- Lead developer
- Ningxia Tianren Goji Biotechnology
- Modality
- Peptides
- Administration
- Oral
01
Overview
Lycium barbarum glycopeptide (LbGp) is a bioactive glycoprotein extracted from the berries of *Lycium barbarum* (Goji), a staple of traditional Chinese medicine. It is a complex molecule consisting of approximately 30% protein linked to glycans, primarily composed of glucose, arabinose, and galactose, via O-linkages. LbGp has demonstrated significant neuroprotective, anti-aging, and antioxidant properties in preclinical models. Its mechanism of action involves the activation of key longevity and stress-response transcription factors, including DAF-16/FOXO, SKN-1/Nrf2, and HSF-1, as well as the modulation of endoplasmic reticulum (ER) stress. LbGp is currently being investigated for its therapeutic potential in treating major depressive disorder (MDD), Parkinson's disease, and normal-tension glaucoma, where it appears to protect retinal ganglion cells and restore neuronal function.
- Other names
- Lycium barbarum glycoproteinLbGPLB glycoproteinsGoji berry glycopeptide
02
Targets
DAF-12 (Nuclear hormone receptor DAF-12)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)HSF1 (Heat shock factor protein 1)FOXO1 (Forkhead box protein O1)
Beyond the preview
Go deeper on lycium barbarum glycopeptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lycium barbarum glycopeptide.